Neurocrine Biosciences

NBIX US Health Care Biotechnology
S&P 400
$156.22
-0.22%
Delayed · cached 15 min
Fair Value Analysis →

Price Chart

Price50-day avg200-day avg

How to read this: the line is the closing price over time. The two dashed lines are moving averages — the average price over the last 50 and 200 trading days — which smooth out daily noise to show the broader trend. Price above its moving averages reflects recent strength; below reflects recent weakness. Use the buttons to change the time range. Prices are end-of-day, not live.

Strengths

  • Return on equity is moderate at 13%.
  • Return on capital employed is moderate at 13.4%.
  • Net profit margin is strong at 16.7%.
  • Current assets comfortably cover current liabilities (current ratio 3.39).

!Watch-points

No notable watch-points flagged by the automated checks.

These points are generated automatically from the company’s reported figures to highlight what stands out. They are descriptive observations for educational purposes only — not advice or a recommendation to buy, sell, or hold.

Forensic Checks

Altman Z-ScoreSafe zone
8.62

In Altman’s original study, companies in this range showed a low incidence of financial distress.

Piotroski F-ScoreModerate
4 / 7

The F-Score adds one point for each of several year-on-year signs of improving profitability, lower leverage and better efficiency. Higher is generally stronger.

Based on 7 of the 9 signals — the rest need data not available for this stock.

These are well-known academic screening models, shown for educational context only. They describe historical financial patterns and are not predictions, advice, or a recommendation to buy, sell, or hold.

Key Ratios

Market Cap$15.88B
Current Price$ 156.22
High / Low$ 186.12 / 122.14
Stock P/E22.839182
Book Value$ 35.45
Dividend Yield0%
ROCE13.41%
ROE12.96%
Current Ratio3.39
P/B Ratio4.2971888
EPS$ 4.67
PAT Margin16.73%
Cash PAT$504.60M
Educational data only. Not a recommendation to buy, sell or hold any security.